AI assistant
Bio Green Med Solution, Inc. — Director's Dealing 2019
Jan 7, 2019
35092_dirs_2019-01-07_506cbebe-7a2e-4cb5-b60f-763f17247691.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cyclacel Pharmaceuticals, Inc. (CYCC)
CIK: 0001130166
Period of Report: 2019-01-03
Reporting Person: Chiao Judy (V.P., Clin. Dev. & Reg. Aff)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-01-04 | Option | $0.71 | A | 284592 | Acquired | 2029-01-04 | Common Stock (284592) | Direct |
| 2019-01-03 | Option | $1.74 | A | 11068 | Acquired | 2027-12-29 | Common Stock (11068) | Direct |
| 2019-01-03 | Option | $1.56 | A | 10183 | Acquired | 2028-02-22 | Common Stock (10183) | Direct |
Footnotes
F1: These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis.
F2: These securities were granted as part of the Issuer's annual compensation review to executive officers.
F3: On December 29, 2017, Judy Chiao was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 11,068 shares.
F4: On February 22, 2018, Judy Chiao was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on January 3, 2019, resulting in the vesting of the option as to 10,183 shares.